NDA 202992 · Sanofi Aventis US
Aubagio
Teriflunomide · Oral · Pyrimidine Synthesis Inhibitor
NovelLast checked: Nov 20, 2026Latest source record: Feb 11, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2012
Sep 12, 2012
Approved uses
4
Original approval plus efficacy supplements
Registered trials
58
30 Phase 3, 3 recruiting
FAERS reports
45,107
19,624 serious, 729 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: HEPATOTOXICITY and EMBRYOFETAL TOXICITY Hepatotoxicity Clinically significant and potentially life-threatening liver injury, including acute liver failure requiring transplant, has been reported in patients treated with AUBAGIO in the postmarketing setting [see Warnings and Precautions (5.1) ] . Concomitant use of AUBAGIO with other hepatotoxic drugs may increase the risk of severe liver injury. Obtain transaminase and bilirubin levels within 6 months before initiation of AUBAGIO therapy. Monitor ALT levels at least monthly for six months after starting AUBAGIO [see Warnings and Precautions (5.1) ]. If drug induced liver injury is suspected, discontinue AUBAGIO and start an accelerated elimination procedure with cholestyramine or charcoal [see Warnings and Precautions (5.3) ] . AUBAGIO is contraindicated in patients with severe hepatic impairment [see Contraindications (4) ] ....
What it is approved for
From the label in effect Feb 20, 2026.
AUBAGIO ® is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. AUBAGIO is a pyrimidine synthesis inhibitor indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. ( 1 )
Mechanism: Teriflunomide, an immunomodulatory agent with anti-inflammatory properties, inhibits dihydroorotate dehydrogenase, a mitochondrial enzyme involved in de novo pyrimidine synthesis. The exact mechanism by which teriflunomide exerts its therapeutic effect in multiple sclerosis is unknown but may involve a reduction in the number of activated lymphocytes in CNS.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 30, 2021 Supplement 13 · Efficacy LetterLabel
- Jul 24, 2019 Supplement 6 · Efficacy LetterLabel
- Oct 17, 2014 Supplement 1 · Efficacy LabelLetter
- Sep 12, 2012 Original approval · Type 1 - New Molecular Entity NovelSummary ReviewLetterLabel
2 products under this application
- AUBAGIO · TERIFLUNOMIDE 7MG · TABLET, ORAL · Prescription · TE AB
- AUBAGIO · TERIFLUNOMIDE 14MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Teriflunomide" as an intervention, any sponsor and status, largest first.
- A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.Pivotal-lookingActive, not recruiting
SanofiSanofi (SNY)
NCT06372145 · 2,500 participants (planned) · Start Apr 16, 2024 · Primary completion Apr 30, 2029
Drug: Tolebrutinib; Placebo and 1 more · For: Relapsing Multiple Sclerosis; Secondary Progressive Multiple Sclerosis; Progressive Relapsing Multiple Sclerosis
Sites: Birmingham, Alabama; Cullman, Alabama; Phoenix, Arizona · 352 sites in all
- A Study to Investigate Long-term Safety and Tolerability of Frexalimab in Participants With Multiple SclerosisPivotal-lookingNot yet recruiting
SanofiSanofi (SNY)
NCT07930624 · 2,500 participants (planned) · Start Feb 15, 2027 · Primary completion May 16, 2031
Drug: Frexalimab; Frexalimab and 6 more · For: Multiple Sclerosis
- Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple SclerosisPivotal-lookingActive, not recruiting
SanofiSanofi (SNY)
NCT06141473 · 1,655 participants · Start Dec 13, 2023 · Primary completion May 6, 2027
Drug: Frexalimab; Teriflunomide and 5 more · For: Multiple Sclerosis
Sites: Birmingham, Alabama; Cullman, Alabama; Homewood, Alabama · 382 sites in all
- An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple SclerosisPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT00751881 · 1,169 participants · Start Aug 2008 · Primary completion Apr 2012
Drug: Placebo; Teriflunomide · For: Multiple Sclerosis
Sites: Phoenix, Arizona; Tucson, Arizona; Loma Linda, California · 193 sites in all
- Study of Evobrutinib in Participants With RMS (evolutionRMS 2)Pivotal-lookingTerminated
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyIndustry
NCT04338061 · 1,166 participants · Start Jul 2, 2020 · Primary completion Oct 2, 2023
Drug: Teriflunomide; Evobrutinib · For: Relapsing Multiple Sclerosis
Sites: Cullman, Alabama; Scottsdale, Arizona; Tucson, Arizona · 278 sites in all
- Oral Ponesimod Versus Teriflunomide In Relapsing MUltiple SclerosisPivotal-lookingCompleted
ActelionJohnson & Johnson (Janssen) (JNJ)
NCT02425644 · 1,133 participants · Start Jun 4, 2015 · Primary completion May 16, 2019
Drug: ponesimod; teriflunomide · For: Multiple Sclerosis
Sites: Carlsbad, California; Pomona, California; Denver, Colorado · 162 sites in all
- Study of Evobrutinib in Participants With RMS (evolutionRMS 1)Pivotal-lookingTerminated
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyIndustry
NCT04338022 · 1,124 participants · Start Jun 12, 2020 · Primary completion Oct 2, 2023
Drug: Teriflunomide; Evobrutinib · For: Relapsing Multiple Sclerosis
Sites: Mobile, Alabama; Phoenix, Arizona; Long Beach, California · 279 sites in all
- Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple SclerosisPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT00134563 · 1,088 participants · Start Sep 2004 · Primary completion Jul 2010
Drug: Teriflunomide; Placebo (for teriflunomide) · For: Multiple Sclerosis
Sites: Bridgewater, New Jersey; Vienna, Austria; Laval, Canada · 21 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- alopecia6,087
- multiple sclerosis relapse5,245
- fatigue4,771
- diarrhoea4,764
- fall3,354
- hypoaesthesia3,173
- headache3,007
- drug ineffective2,833
- paraesthesia2,816
- nausea2,749
- gait disturbance2,496
- pain2,239
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2007 | 1 |
| 2010 | 3 |
| 2011 | 2 |
| 2012 | 18 |
| 2013 | 1,900 |
| 2014 | 3,391 |
| 2015 | 2,733 |
| 2016 | 3,416 |
| 2017 | 4,323 |
| 2018 | 4,545 |
| 2019 | 4,640 |
| 2020 | 3,161 |
| 2021 | 6,639 |
| 2022 | 5,679 |
| 2023 | 2,621 |
| 2024 | 938 |
| 2025 | 660 |
| 2026 | 437 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Aubagio (Teriflunomide)
2024 spending
$148M
Beneficiaries
2,229
14,264 claims
Per beneficiary
$66,613
$302.42 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $778,201,329 |
| 2021 | $724,520,395 |
| 2022 | $696,532,583 |
| 2023 | $353,934,133 |
| 2024 | $148,480,748 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Ofatumumab versus Teriflunomide in Multiple Sclerosis.
Hauser SL, Bar-Or A, Cohen JA, et al. · N Engl J Med 2020 · Clinical Trial, Phase III, Comparative Study
- Tolebrutinib versus Teriflunomide in Relapsing Multiple Sclerosis.
Oh J, Arnold DL, Cree BAC, et al. · N Engl J Med 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis.
Gonzalez-Lorenzo M, Ridley B, Minozzi S, et al. · Cochrane Database Syst Rev 2024 · Systematic Review, Network Meta-Analysis
- Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis.
Steinman L, Fox E, Hartung HP, et al. · N Engl J Med 2022 · Clinical Trial, Phase III, Randomized Controlled Trial
- Drug-Induced Progressive Multifocal Leukoencephalopathy (PML): A Systematic Review and Meta-Analysis.
Rindi LV, Zaçe D, Braccialarghe N, et al. · Drug Saf 2024 · Systematic Review, Meta-Analysis
- Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: The ALITHIOS open-label extension.
Hauser SL, Zielman R, Das Gupta A, et al. · Mult Scler 2023 · Randomized Controlled Trial, Research Support, N.I.H., Extramural
Sponsor: Sanofi
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.